A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study
详细信息 查看全文
- 作者：Qader Motarjemizadeh ; Naser Samadi Aidenloo ; Siamak Sepehri
- 关键词：Pterygium ; Recurrence ; Bevacizumab ; Bare sclera ; Iran
- 刊名：International Ophthalmology
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：36
- 期：1
- 页码：63-71
- 全文大小：398 KB
- 参考文献：1.Farrah JJ, Lee GA, Greenrod E, Vieira J (2006) Outcomes of autoconjunctival grafting for primary pterygia when performed by consultant compared with trainee ophthalmologists. Clin Exp Ophthalmol 34(9):857–860. doi:10.1111/j.1442-9071.2006.01341.x CrossRef
2.Pinkerton OD, Hokama Y, Shigemura LA (1984) Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol 98(2):225–228PubMed CrossRef
3.Papadia M, Barabino S, Valente C, Rolando M (2008) Anatomical and immunological changes of the cornea in patients with pterygium. Curr Eye Res 33(5):429–434. doi:10.1080/02713680802130354 PubMed CrossRef
4.Chui J, Di Girolamo N, Wakefield D, Coroneo MT (2008) The pathogenesis of pterygium: current concepts and their therapeutic implications. Ocul Surf 6(1):24–43PubMed CrossRef
5.Mauro J, Foster CS (2009) Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment. Semin Ophthalmol 24(3):130–134. doi:10.1080/08820530902801106 PubMed CrossRef
6.Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25(2):111–118PubMed CrossRef
7.Hosseini H, Nejabat M, Khalili MR (2007) Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 69(4):925–927. doi:10.1016/j.mehy.2007.01.047 PubMed CrossRef
8.Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13(1):9–22PubMed
9.Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, Dana R (2012) Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf 10(2):67–83. doi:10.1016/j.jtos.2012.01.005 PubMed PubMedCentral CrossRef
10.Galor A, Yoo SH, Piccoli FV, Schmitt AJ, Chang V, Perez VL (2010) Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. Am J Ophthalmol 149(6):926–931. doi:10.1016/j.ajo.2010.01.015 PubMed CrossRef
11.Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333(2):328–335. doi:10.1016/j.bbrc.2005.05.132 PubMed CrossRef
12.Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342. doi:10.1056/NEJMoa032691 PubMed CrossRef
13.Leippi S, Grehn F, Geerling G (2009) Antiangiogenic therapy for pterygium recurrence. Ophthalmologe 106(5):413–419. doi:10.1007/s00347-009-1936-y PubMed CrossRef
14.Ozgurhan EB, Agca A, Kara N, Yuksel K, Demircan A, Demirok A (2013) Topical application of bevacizumab as an adjunct to recurrent pterygium surgery. Cornea 32(6):835–838. doi:10.1097/ICO.0b013e3182772d4e PubMed CrossRef
15.Wu PC, Kuo HK, Tai MH, Shin SJ (2009) Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 28(1):103–104. doi:10.1097/ICO.0b013e3181822615 PubMed CrossRef
16.Sanchez-Thorin JC, Rocha G, Yelin JB (1998) Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium. Br J Ophthalmol 82(6):661–665PubMed PubMedCentral CrossRef
17.Fallah MR, Khosravi K, Hashemian MN, Beheshtnezhad AH, Rajabi MT, Gohari M (2010) Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res 35(1):17–22. doi:10.3109/02713680903395273 PubMed CrossRef
18.D’Ombrain A (1948) The surgical treatment of pterygium. Br J Ophthalmol 32(2):65–71PubMed PubMedCentral CrossRef
19.Andreoli CM, Miller JW (2007) Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 18(6):502–508. doi:10.1097/ICU.0b013e3282f0ca54 PubMed CrossRef
20.Manayath GJ, Narendran V, Al-Kharousi N, Wali UK (2009) Bevacizumab therapy for macular edema in central retinal vein occlusion: long-term results. Oman J Ophthalmol 2(2):73–78. doi:10.4103/0974-620X.53036 PubMed PubMedCentral CrossRef
21.Jardeleza MS, Miller JW (2009) Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol 24(2):87–92. doi:10.1080/08820530902800330 PubMed CrossRef
22.El-Mollayess GM, Noureddine BN, Bashshur ZF (2011) Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment. Semin Ophthalmol 26(3):69–76. doi:10.3109/08820538.2010.545100 PubMed CrossRef
23.Martinez-Carpio PA, Bonafonte-Marquez E, Heredia-Garcia CD, Bonafonte-Royo S (2008) Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review. Arch Soc Esp Oftalmol 83(10):579–588PubMed CrossRef
24.Bock F, Konig Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246(2):281–284. doi:10.1007/s00417-007-0684-4 PubMed CrossRef
25.Chen JJ, Ebmeier SE, Sutherland WM, Ghazi NG (2011) Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye. Eye (Lond) 25(11):1504–1511. doi:10.1038/eye.2011.225 CrossRef
26.Karalezli A, Kucukerdonmez C, Akova YA, Koktekir BE (2014) Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting? Int J Ophthalmol 7(3):512–516. doi:10.3980/j.issn.2222-3959.2014.03.23 PubMed PubMedCentral
27.Sudhalkar A, Sudhalkar A (2012) Outcomes of post-operative topical bevacizumab in primary pterygium surgery: a case series. J Clin Exp Ophthalmol 3(7):243. doi:10.4172/2155-9570.1000243 CrossRef
28.Alhammami H, Farhood Q, Shuber H (2013) Subconjunctival Bevacizumab Injection in Treatment of recurrent Pterygium. J Clin Exp Ophthal 4(267):2. doi:10.4172/2155-9570.1000267
29.Nava-Castaneda A, Olvera-Morales O, Ramos-Castellon C, Garnica-Hayashi L, Garfias Y (2014) Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1 year follow-up. Clin Exp Ophthalmol 42(3):235–241. doi:10.1111/ceo.12140 CrossRef
30.Felipe AF, Siong RLB, Uy HS (2009) Subconjunctival injection of bevacizumab for treatment of pterygium. Phillip J Ophthalmol 34(1):44–50
31.Khoshniat H, Jahadi Hosseini H, Nejabat M, Fatehi K, Mosallaei M (2009) Local injection of bevacizumab as an alternative method for management of recurrent pterygium. Iran Red Crescent Med J 11(3):306–311
32.Waisbourd M, Levinger E, Varssano D, Moisseiev E, Zayit-Soudri S, Barak A, Loewenstein A, Barequet I (2013) High-dose topical bevacizumab for corneal neovascularization. Pharmacology 92(5–6):310–314. doi:10.1159/000356407 PubMed CrossRef
33.Razeghinejad R, Banifatemi M, Hosseini H (2013) The effect of different doses of subconjunctival bevacizumab on the recurrence rate of excised primary pterygium. Bull Soc Belge Ophtalmol 322:13–20PubMed
34.Prabhasawat P, Barton K, Burkett G, Tseng SC (1997) Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology 104(6):974–985PubMed CrossRef - 作者单位：Qader Motarjemizadeh (1)
Naser Samadi Aidenloo (1)
Siamak Sepehri (1)
1. Department of Ophthalmology, Medical University of Urmia, 57147-83734, Urmia, Iran - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Ophthalmology - 出版者：Springer Netherlands
- ISSN：1573-2630
文摘
The present study was undertaken to compare the pterygium recurrence rates after treatment with two different concentrations of topical bevacizumab in those who had undergone a primary pterygium excision. The 90 patients who underwent pterygium excision were enrolled in this prospective, placebo-controlled double-blinded interventional case series. The participants were randomly categorized into 3 groups each consisting of 30 subjects. 24 h after surgery, Group II and Group III received a total of 5 and 10 mg/mL dose of topical bevacizumab, respectively; whereas patients in Group I were administered only a placebo starting a day after surgery. Participants were instructed to instill their topical medicines 4 times a day for 1 week. The patients were examined for pterygium recurrence and complications at postoperative 1, 7, and 14 days as well as each month during the following year. Pterygia recurred in 14 patients (46.7 %) in Group I and in 4 patients (13.3 %) in Group II. No recurrence was observed in Group III during the follow-up period. The Kaplan–Meier survival analysis disclosed a significantly better outcome for those who had been treated with 10 mg/mL concentrations of bevacizumab (Mantel–Cox log rank analysis, P < 0.001). The mean recurrence time was not significantly different between Group I and Group II. No ocular or systemic complication developed till the end of follow-up. Thus, 10 mg/mL concentration of topical bevacizumab was more efficacious than 5 mg/mL dose in preventing pterygium recurrence. Keywords Pterygium Recurrence Bevacizumab Bare sclera Iran